BioCentury | Aug 11, 2011
Targets & Mechanisms

Gutsy call on Th17 cells

...children and adults with recent-onset type 1 diabetes. In March, the anti-CD3 mAb otelixizumab from Tolerx Inc....
...plc failed in the Phase III DEFEND-1 trial in patients with new-onset type 1 diabetes. Tolerx...
...Md. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Tempero Pharmaceuticals Inc. , Cambridge, Mass. Tolerx Inc....
BioCentury | Jul 28, 2011
Targets & Mechanisms

A stimulating insulin vaccine

...Lilly and Co. 's teplizumab anti-CD3 mAb failed in a Phase II/III trial. In March, Tolerx Inc....
...Jolla Institute for Allergy & Immunology , La Jolla, Calif. MacroGenics Inc. , Rockville, Md. Tolerx Inc....
BioCentury | Jul 4, 2011
Company News

Euthymics management update

...Bioscience Inc. , Cambridge, Mass. Business: Neurology Hired: Thomas Shea as CFO, formerly CFO of Tolerx Inc. WIR...
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

...NASDAQ:TRGT) TC-5619 fails in a Phase II trial to treat ADHD in patients ages 18-65 Tolerx Inc./GlaxoSmithKline...
BioCentury | Mar 14, 2011
Finance

Still some pop in Benlysta

...technology (see B13) . BTG plc (LSE:BGC) gained 1.90p to 217.60p on Friday even as Tolerx Inc....
...BTG, which was up 3.20p on the week, granted worldwide rights for otelixizumab to Tolerx...
BioCentury | Mar 14, 2011
Finance

Highlights of weekly biotech stock moves

...technology (see B13) . BTG plc (LSE:BGC) gained 1.90p to 217.60p on Friday even as Tolerx Inc....
...BTG, which was up 3.20p on the week, granted worldwide rights for otelixizumab to Tolerx...
BioCentury | Mar 14, 2011
Clinical News

Otelixizumab: Phase III data

...clinical development program for the compound. In 2001, BTG granted worldwide rights for otelixizumab to Tolerx...
...develop and commercialize the product (see BioCentury, Oct. 29, 2007). BTG plc (LSE:BGC), London, U.K. Tolerx Inc....
BioCentury | Mar 12, 2011
Top Story

Otelixizumab misses diabetes endpoint

...for rheumatoid arthritis (RA). In 2001, BTG plc (LSE:BGC) granted worldwide rights for otelixizumab to Tolerx...
BioCentury | Feb 24, 2011
Distillery Techniques

Technology: Disease models

...with no treatment. Next steps could include using the model to test other anti-CD3 antibodies. Tolerx Inc....
BioCentury | Feb 21, 2011
Clinical News

Tolerx preclinical data

...melanoma. Data were presented at the Keystone Symposia on Antibodies as Drugs meeting in Keystone. Tolerx Inc....
Items per page:
1 - 10 of 94
BioCentury | Aug 11, 2011
Targets & Mechanisms

Gutsy call on Th17 cells

...children and adults with recent-onset type 1 diabetes. In March, the anti-CD3 mAb otelixizumab from Tolerx Inc....
...plc failed in the Phase III DEFEND-1 trial in patients with new-onset type 1 diabetes. Tolerx...
...Md. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Tempero Pharmaceuticals Inc. , Cambridge, Mass. Tolerx Inc....
BioCentury | Jul 28, 2011
Targets & Mechanisms

A stimulating insulin vaccine

...Lilly and Co. 's teplizumab anti-CD3 mAb failed in a Phase II/III trial. In March, Tolerx Inc....
...Jolla Institute for Allergy & Immunology , La Jolla, Calif. MacroGenics Inc. , Rockville, Md. Tolerx Inc....
BioCentury | Jul 4, 2011
Company News

Euthymics management update

...Bioscience Inc. , Cambridge, Mass. Business: Neurology Hired: Thomas Shea as CFO, formerly CFO of Tolerx Inc. WIR...
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

...NASDAQ:TRGT) TC-5619 fails in a Phase II trial to treat ADHD in patients ages 18-65 Tolerx Inc./GlaxoSmithKline...
BioCentury | Mar 14, 2011
Finance

Still some pop in Benlysta

...technology (see B13) . BTG plc (LSE:BGC) gained 1.90p to 217.60p on Friday even as Tolerx Inc....
...BTG, which was up 3.20p on the week, granted worldwide rights for otelixizumab to Tolerx...
BioCentury | Mar 14, 2011
Finance

Highlights of weekly biotech stock moves

...technology (see B13) . BTG plc (LSE:BGC) gained 1.90p to 217.60p on Friday even as Tolerx Inc....
...BTG, which was up 3.20p on the week, granted worldwide rights for otelixizumab to Tolerx...
BioCentury | Mar 14, 2011
Clinical News

Otelixizumab: Phase III data

...clinical development program for the compound. In 2001, BTG granted worldwide rights for otelixizumab to Tolerx...
...develop and commercialize the product (see BioCentury, Oct. 29, 2007). BTG plc (LSE:BGC), London, U.K. Tolerx Inc....
BioCentury | Mar 12, 2011
Top Story

Otelixizumab misses diabetes endpoint

...for rheumatoid arthritis (RA). In 2001, BTG plc (LSE:BGC) granted worldwide rights for otelixizumab to Tolerx...
BioCentury | Feb 24, 2011
Distillery Techniques

Technology: Disease models

...with no treatment. Next steps could include using the model to test other anti-CD3 antibodies. Tolerx Inc....
BioCentury | Feb 21, 2011
Clinical News

Tolerx preclinical data

...melanoma. Data were presented at the Keystone Symposia on Antibodies as Drugs meeting in Keystone. Tolerx Inc....
Items per page:
1 - 10 of 94